Predictive assessment in pharmacogenetics of XRCC1 gene on clinical outcomes of advanced lung cancer patients treated with platinum-based chemotherapy

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Yuan, Zhengrong ^a,b   Li, Jiao ^c   Hu, Ruiqi ^a   Jiao, Yang ^a   Han, Yingying ^a   Weng, Qiang ^a  

^a BEIJING FORESTRY UNIVERSITY   (China)

^b INSTITUTE OF MEDICINAL PLANT DEVELOPMENT   (China)

^c National Animal Husbandry Service   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; DNA BINDING PROTEIN; PLATINUM; X-RAY REPAIR CROSS COMPLEMENTING PROTEIN 1;

GENETIC PREDISPOSITION; GENETICS; GENOTYPE; HUMAN; LUNG NEOPLASMS; META ANALYSIS; ODDS RATIO; PHARMACOGENETICS; PROGNOSIS; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DNA-BINDING PROTEINS; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; LUNG NEOPLASMS; ODDS RATIO; PHARMACOGENETICS; PLATINUM; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; TREATMENT OUTCOME;

EID: 84947767182     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep16482     Document Type: Article

References (111)

1. Jemal, A. et al. Global cancer statistics. CA: A Cancer Journal for Clinicians 61, 69-90 (2011).
2. Parkin, D. M., Bray, F., Ferlay, J., Pisani, P. Global cancer statistics, 2002. CA: A Cancer Journal for Clinicians 55, 74-108 (2005).
3. Molina, J. R., Yang, P., Cassivi, S. D., Schild, S. E., Adjei, A. A. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clinic Proceedings 83, 584-594 (2008).
4. Herbst, R. S., Heymach, J. V., Lippman, S. M. Lung cancer. The New England Journal of Medicine 359, 1367-1380 (2008).
5. Spiro, S. G., Silvestri, G. A. The treatment of advanced non-small cell lung cancer. Current Opinion in Pulmonary Medicine 11, 287-291 (2005).
6. Yuan, P. et al. No association between XRCC1 polymorphisms and survival in non-small-cell lung cancer patients treated with platinum-based chemotherapy. Cancer Biology & Therapy 10, 854-859 (2010).
7. Peng, Y. et al. Association of DNA base excision repair genes (OGG1, APE1 and XRCC1) polymorphisms with outcome to platinum-based chemotherapy in advanced nonsmall-cell lung cancer patients. International Journal of Cancer 135, 2687-2696 (2014).
8. Du, Y. et al. Associations of polymorphisms in DNA repair genes and MDR1 gene with chemotherapy response and survival of non-small cell lung cancer. PLoS One 9, e99843 (2014).
9. Wu, L. et al. Development of autoantibody signatures as novel diagnostic biomarkers of non-small cell lung cancer. Clinical Cancer Research 16, 3760-3768 (2010).
10. Gurubhagavatula, S. et al. XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy. Journal of Clinical Oncology 22, 2594-2601 (2004).
11. Bosken, C. H., Wei, Q., Amos, C. I., Spitz, M. R. An analysis of DNA repair as a determinant of survival in patients with non-small-cell lung cancer. Journal of the National Cancer Institute 94, 1091-1099 (2002).
12. Wang, L. E. et al. DNA repair capacity in peripheral lymphocytes predicts survival of patients with non-small-cell lung cancer treated with first-line platinum-based chemotherapy. Journal of Clinical Oncology 29, 4121-4128 (2011).
13. Bahl, A., Falk, S. Meta-analysis of single agents in the chemotherapy of NSCLC: what do we want to know British Journal of Cancer 84, 1143-1145 (2001).
14. Cui, Z. et al. Association between polymorphisms in XRCC1 gene and clinical outcomes of patients with lung cancer: a metaanalysis. BMC Cancer 12, 71 (2012).
15. Yin, J. Y., Huang, Q., Zhao, Y. C., Zhou, H. H., Liu, Z. Q. Meta-analysis on pharmacogenetics of platinum-based chemotherapy in non small cell lung cancer (NSCLC) patients. PLoS One 7, e38150 (2012).
16. Chen, J., Zhao, Q. W., Shi, G. M., Wang, L. R. XRCC1 Arg399Gln and clinical outcome of platinum-based treatment for advanced non-small cell lung cancer: a meta-analysis in 17 studies. Journal of Zhejiang University SCIENCE B 13, 875-883 (2012).
17. Abdel-Rahman, S. Z., El-Zein, R. A. The 399Gln polymorphism in the DNA repair gene XRCC1 modulates the genotoxic response induced in human lymphocytes by the tobacco-specific nitrosamine NNK. Cancer Letters 159, 63-71 (2000).
18. Matullo, G. et al. XRCC1, XRCC3, XPD gene polymorphisms, smoking and (32)P-DNA adducts in a sample of healthy subjects. Carcinogenesis 22, 1437-1445 (2001).
19. Bernig, T., Chanock, S. J. Challenges of SNP genotyping and genetic variation: its future role in diagnosis and treatment of cancer. Expert Review of Molecular Diagnostics 6, 319-331 (2006).
20. Wood, R. D., Mitchell, M., Sgouros, J., Lindahl, T. Human DNA repair genes. Science 291, 1284-1289 (2001).
21. Lindahl, T., Wood, R. D. Quality control by DNA repair. Science 286, 1897-1905 (1999).
22. Thompson, L. H., Brookman, K. W., Jones, N. J., Allen, S. A., Carrano, A. V. Molecular cloning of the human XRCC1 gene, which corrects defective DNA strand break repair and sister chromatid exchange. Molecular and Cellular Biology 10, 6160-6171 (1990).
23. Hoeijmakers, J. H. Genome maintenance mechanisms for preventing cancer. Nature 411, 366-374 (2001).
24. Whitehouse, C. J. et al. XRCC1 stimulates human polynucleotide kinase activity at damaged DNA termini and accelerates DNA single-strand break repair. Cell 104, 107-117 (2001).
25. Savas, S., Kim, D. Y., Ahmad, M. F., Shariff, M., Ozcelik, H. Identifying functional genetic variants in DNA repair pathway using protein conservation analysis. Cancer Epidemiology, Biomarkers & Prevention 13, 801-807 (2004).
26. Mohrenweiser, H. W., Xi, T., Vazquez-Matias, J., Jones, I. M. Identification of 127 amino acid substitution variants in screening 37 DNA repair genes in humans. Cancer Epidemiology, Biomarkers & Prevention 11, 1054-1064 (2002).
27. Zhu, G., Lippard, S. J. Photoaffinity labeling reveals nuclear proteins that uniquely recognize cisplatin-DNA interstrand crosslinks. Biochemistry 48, 4916-4925 (2009).
28. Audebert, M., Salles, B., Calsou, P. Involvement of poly(ADP-ribose) polymerase-1 and XRCC1/DNA ligase III in an alternative route for DNA double-strand breaks rejoining. The Journal of Biological Chemistry 279, 55117-55126 (2004).
29. Wang, Z. H. et al. Single nucleotide polymorphisms in XRCC1 and clinical response to platin-based chemotherapy in advanced non-small cell lung cancer. Chinese Journal of Cancer 23, 865-868 (2004).
30. Gao, C. M. et al. Polymorphisms in XRCC1 gene and sensitivity to gemcitabine/cisplat in chemotherapy in non small cell lung cancer. The Practical Journal of Cancer 21, 351-353 (2006).
31. Yuan, P. et al. XRCC1 and XPD genetic polymorphisms predict clinical responses to platinum-based chemotherapy in advanced non-small cell lung cancer. Zhonghua Zhong Liu Za Zhi 28, 196-199 (2006).
32. Shi, M. Q. et al. Polymorphisms in XRCC1 gene and sensitivity to platin-based chemotherapy in advanced lung cancer. Chinese Clinical Oncology 11, 575-578-584 (2006).
33. Jin, Y. W., Liu, J., Wang, Z. H. Prediction of XPD and XRCC1 gene polymorphisms in advanced non-small cell lung cancer patients receiving platinum-based chemotherapy. Shandong Medical Journal 46, 42-43 (2006).
34. de las Penas, R. et al. Polymorphisms in DNA repair genes modulate survival in cisplatin/gemcitabine-treated non-small-cell lung cancer patients. Annals of Oncology 17, 668-675 (2006).
35. Wang, Z. H. et al. Polymorphisms of DNA X-ray repair cross complementary protein 1 and its association with survival to platin-based chemotherapy in advanced non-small cell lung cancer. Clinical Medicine of China 22, 1-3 (2006).
36. Song, D., Liu, J., Wang, Z., Song, B., Li, C. Single nucleotide polymorphisms in XRCC1 and clinical response to platin-based chemotherapy in advanced non-small cell lung cancer. Cancer Research on Prevention and Treatment 34, 845-847 (2007).
37. Giachino, D. F. et al. Prospective assessment of XPD Lys751Gln and XRCC1 Arg399Gln single nucleotide polymorphisms in lung cancer. Clinical Cancer Research 13, 2876-2881 (2007).
38. Song, D., Liu, J., Wang, Z., Song, B., Li, C. Single nucleotide polymorphisms in XRCC1 and XPD and clinical response to platin-based chemotherapy in advanced non-small cell lung cancer. Chinese Journal of Gerontology 27, 1684-1686 (2007).
39. Chen, X. X. The relationship between response to platinum-based regimens chemotherapy and genetic polymorphisms of DNA repair enzyme XRCC1 and the effect on the patients' quality of life in advanced non-small cell lung cancer. Anhui Medical University, Master thesis, (2007).
40. Liu, X. Z. et al. Single nucleotide polymorphism in XRCC2, XPD and platinum prognosis in non-small cell lung cancer patients. Journal of Clinical Medicine in Practice 12, 7-12 (2008).
41. Fan, H. et al. Relationship of XRCC1 and XPD gene polymorphisms with chemosensitivity to platinum-based chemotherapy in advanced non-small cell lung cancer. Practical Geriatrics 22, 306-314 (2008).
42. Qiu, L. X. et al. Predictive value of XRCC1 polymorphisms in advanced non-small cell lung cancer patients receiving platinumbased chemotherapy. Modern Oncology 17, 263-265 (2009).
43. Sun, X. et al. Polymorphisms in XRCC1 and XPG and response to platinum-based chemotherapy in advanced non-small cell lung cancer patients. Lung Cancer 65, 230-236 (2009).
44. Hong, C. Y., Xu, Q., Yue, Z., Zhang, Y., Yuan, Y. Correlation of the sensitivity of NP chemotherapy in non-small lung cancer with DNA repair gene XRCC1 polymorphism. Chinese Journal of Cancer 28, 1291-1297 (2009).
45. Kalikaki, A. et al. DNA repair gene polymorphisms predict favorable clinical outcome in advanced non-small-cell lung cancer. Clinical Lung Cancer 10, 118-123 (2009).
46. Yao, C. Y. et al. Lack of influence of XRCC1 and XPD gene polymorphisms on outcome of platinum-based chemotherapy for advanced non small cell lung cancers. Asian Pacific Journal of Cancer Prevention 10, 859-864 (2009).
47. Qiu, L. X. XRCC1, ADPRT gene polymorphism and TS gene expression and malignant tumor chemosensitivity relationship experiments and evidence-based medical research. Nanjing Medical University, Master thesis, (2009).
48. Ding, C. L., Liu, L. H., Song, H. F. Polymorphism in XRCC1 and sensitivity to platin-based chemotherapy in advanced nonsmall cell lung cancer. China Pharmacist 13, 1399-1401 (2010).
49. Qian, X. P. et al. Predictive value of base-excision repair gene polymorphisms in advanced non-small cell lung cancer patients receiving platinum-based chemotherapy. Modern Oncology 18, 1303-1304 (2010).
50. Ying, R. B., Chen, M. C., Qu, H. J., Li, J. J. The predictive value of XRCC1 gene polymorphisms on the sensitivity of platinumbased chemotherapy in advanced non-small cell lung cancer. China Higher Medical Education 28, 142-143 (2010).
51. Cheng, H. Y. et al. Relationship of single nucleotide polymorphisms and clinical response to platinum-based chemotherapy in advanced non-small cell lung cancer. Jiangsu Medical Journal 37, 272-274 (2011).
52. Cheng, H. Y. et al. Polymorphisms of ERCC1, XRCC1 and its association with survival to platin-based chemotherapy in advanced non-small cell lung cancer. Journal of Southeast University (Medical Science Edition) 30, 717-721 (2011).
53. Han, J. Y. et al. DNA repair gene polymorphisms and benefit from gefitinib in never-smokers with lung adenocarcinoma. Cancer 117, 3201-3208 (2011).
54. Zhou, F. et al. Genetic polymorphisms of GSTP1 and XRCC1: prediction of clinical outcome of platinum-based chemotherapy in advanced non-small cell lung cancer (NSCLC) patients. Swiss Medical Weekly 141, w13275 (2011).
55. Zhou, F. et al. Association of GSTP1 and XRCC1 genetic polymorphisms with the effects of platinum-based chemotherapy on advanced non-small cell lung cancer patients. Chinese Clinical Oncology 16, 304-309 (2011).
56. Han, Y. et al. ERCC1 and XRCC1 gene polymorphisms and clinical response to platinum-based chemotherapy in advanced non-small cell lung cancer. Chinese Journal of Practical Internal Medicine 31, 638-639 (2011).
57. Xu, C. A., Wang, X. J., Zhang, Y., Li, L. Effect of the XRCC1 and XRCC3 Genetic Polymorphisms on the Efficacy of Platinumbased Chemotherapy in Patients with Advanced Non-small Cell Lung Cancer. Chinese Journal of Lung Cancer 14, 912-917 (2011).
58. Hong, X. H. Genetic polymorphisms of XPA, XPC and XRCC1 are correlated with the prognosis of non-small-cell lung cancer patients treated with platinum-based chemotherapy. Huazhong University of Science and Technology, Master thesis, (2011).
59. Joerger, M. et al. Germline polymorphisms in patients with advanced nonsmall cell lung cancer receiving first-line platinumgemcitabine chemotherapy: a prospective clinical study. Cancer 118, 2466-2475 (2012).
60. Li, D., Zhou, Q., Liu, Y., Yang, Y., Li, Q. DNA repair gene polymorphism associated with sensitivity of lung cancer to therapy. Medical Oncology 29, 1622-1628 (2012).
61. Xu, C. A., Li, Q., Wang, X. J., Li, L. Sensitivity relationship of ERCC1 and XRCC1 genetic polymorphism on response of platinum-based chemotherapy in advanced NSCLC. Journal of Practical Oncology 37, 245-250 (2012).
62. Zha, Y. Y. et al. Correlation Between the Short-term Effect of NP Chemotherapy Regiment Combined with Radiotherapy in the Treatment of Stage III NSCLC and Single Nucleotide Polymorphism of XRCC1 Gene Codon399. The Practical Journal of Cancer 27, 472-474 (2012).
63. Ke, H. G. et al. Prognostic significance of GSTP1, XRCC1 and XRCC3 polymorphisms in non-small cell lung cancer patients. Asian Pacific Journal of Cancer Prevention 13, 4413-4416 (2012).
64. Liao, W. Y. et al. Genetic polymorphism of XRCC1 Arg399Gln is associated with survival in non-small-cell lung cancer patients treated with gemcitabine/platinum. Journal of Thoracic Oncology 7, 973-981 (2012).
65. Liu, H. N., Liu, Y. P., Xue, H. B., Deng, Y. Q., Ling, Y. Association of repair gene polymorphisms with clinical response to platinum-based chemotherapy in advanced lung cancer. Modern Medical Journal 41, 659-661 (2013).
66. Li, H., Huang, Y. C., Feng, Y. Association between XRCC1 Arg399 Gln Polymorphisms in Non-small Cell Lung Cancer with Efficacy of Platinum-based Chemotherapy. Journal of Kunming Medical University 34, 82-84 (2013).
67. Yang, W. J., Wang, N. J., Chen, D. M. Mutation in XRCC1, Polymorphism in RRM1 and Efficacy of Platin-based Chemotherapy in Patients with Advanced Non-small Cell Lung Cancer. Journal of Ningxia Medical University 35, 13-17 (2013).
68. Sheng, G. F. et al. Relationship of XRCC1 and efficacy of platinum-based chemotherapy in advanced non-small cell lung cancer. Jiangsu Medical Journal 39, 295-297 (2013).
69. Lee, S. Y. et al. Polymorphisms in DNA repair and apoptosis-related genes and clinical outcomes of patients with non-small cell lung cancer treated with first-line paclitaxel-cisplatin chemotherapy. Lung Cancer 82, 330-339 (2013).
70. Liu, L. et al. Multi-loci analysis reveals the importance of genetic variations in sensitivity of platinum-based chemotherapy in non-small-cell lung cancer. Molecular Carcinogenesis 52, 923-931 (2013).
71. Zhao, W. et al. Polymorphisms in the base excision repair pathway modulate prognosis of platinum-based chemotherapy in advanced non-small cell lung cancer. Cancer Chemotherapy and Pharmacology 71, 1287-1295 (2013).
72. Deng, J. H. Study on the relationship between efficacy and toxicity of cisplatin and single nucleotide polymorphisms in advanced non-small cell lung cancer patients. Fujian Medical University, Master thesis (2013).
73. Zhou, G. R. et al. Polymorphism of XRCC1 and ERCC1 single nucleotide and sensitivity of non-small cell lung cancer to platinum-based chemotherapy. Journal of Hainan Medical University 20, 20-24 (2014).
74. Zhang, L., Ma, W., Li, Y., Wu, J., Shi, G. Y. Pharmacogenetics of DNA repair gene polymorphisms in non-small-cell lung carcinoma patients on platinum-based chemotherapy. Genetics and molecular research 13, 228-236 (2014).
75. Jin, Z. Y. et al. Effects of polymorphisms in the XRCC1, XRCC3, and XPG genes on clinical outcomes of platinum-based chemotherapy for treatment of non-small cell lung cancer. Genetics and molecular research 13, 7617-7625 (2014).
76. Sullivan, I. et al. Pharmacogenetics of the DNA repair pathways in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy. Cancer Letters 353, 160-166 (2014).
77. Liu, D. S. The associaton of between the sensitivity of NP chemotherapy in non-small lung cancer and DNA repair gene XRCC1 polymorphisms. Contemporary Medicine Forum 12, 210-211 (2014).
78. Kalikaki, A. et al. ERCC1 SNPs as Potential Predictive Biomarkers in Non-Small Cell Lung Cancer Patients Treated With Platinum-Based Chemotherapy. Cancer Investigation 33, 107-113 (2015).
79. Wu, J. et al. Predictive value of XRCC1 gene polymorphisms on platinum-based chemotherapy in advanced non-small cell lung cancer patients: a systematic review and meta-analysis. Clinical Cancer Research 18, 3972-3981 (2012).
80. Li, L., Wan, C., Wen, F. Q. Polymorphisms in the XRCC1 gene are associated with treatment response to platinum chemotherapy in advanced non-small cell lung cancer patients based on meta-analysis. Genetics and molecular research 13, 3772-3786 (2014).
81. Gu, A. Q. et al. XRCC1 genetic polymorphisms and sensitivity to platinum-based drugs in non-small cell lung cancer: an update meta-analysis based on 4708 subjects. International Journal of Clinical and Experimental Medicine 8, 145-154 (2015).
82. Yamaguchi, M., Sugio, K. Current status of induction treatment for N2-Stage III non-small cell lung cancer. General Thoracic and Cardiovascular Surgery 62, 651-659 (2014).
83. Cao, Z. et al. Association between polymorphisms in XRCC1 gene and treatment outcomes of patients with advanced gastric cancer: a systematic review and meta-analysis. PLoS One 9, e85357 (2014).
84. Nagasubramanian, R., Innocenti, F., Ratain, M. J. Pharmacogenetics in cancer treatment. Annual Review of Medicine 54, 437-452 (2003).
85. Marsh, S., McLeod, H. L. Cancer pharmacogenetics. British Journal of Cancer 90, 8-11 (2004).
86. Weaver, D. A. et al. ABCC5, ERCC2, XPA and XRCC1 transcript abundance levels correlate with cisplatin chemoresistance in non-small cell lung cancer cell lines. Molecular Cancer 4, 18 (2005).
87. Horgan, A. M. et al. Pharmacogenetic and germline prognostic markers of lung cancer. Journal of Thoracic Oncology 6, 296-304 (2011).
88. Park, J. Y. et al. Polymorphism of the DNA repair gene XRCC1 and risk of primary lung cancer. Cancer Epidemiology Biomarkers & Prevention 11, 23-27 (2002).
89. Zhou, W. et al. Polymorphisms in the DNA repair genes XRCC1 and ERCC2, smoking, and lung cancer risk. Cancer Epidemiology Biomarkers & Prevention 12, 359-365 (2003).
90. Zienolddiny, S. et al. Polymorphisms of DNA repair genes and risk of non-small cell lung cancer. Carcinogenesis 27, 560-567 (2006).
91. De Ruyck, K. et al. Polymorphisms in base-excision repair and nucleotide-excision repair genes in relation to lung cancer risk. Mutation research 631, 101-110 (2007).
92. Li, M. et al. XRCC1 polymorphisms, cooking oil fume and lung cancer in Chinese women nonsmokers. Lung Cancer 62, 145-151 (2008).
93. Yin, Z. et al. Association between polymorphisms in DNA repair genes and survival of non-smoking female patients with lung adenocarcinoma. BMC Cancer 9, 439 (2009).
94. Sreeja, L. et al. Prognostic importance of DNA repair gene polymorphisms of XRCC1 Arg399Gln and XPD Lys751Gln in lung cancer patients from India. Journal of Cancer Research and Clinical Oncology 134, 645-652 (2008).
95. Lunn, R. M., Langlois, R. G., Hsieh, L. L., Thompson, C. L., Bell, D. A. XRCC1 polymorphisms: effects on aflatoxin B1-DNA adducts and glycophorin A variant frequency. Cancer Research 59, 2557-2561 (1999).
96. Shen, M. R., Jones, I. M., Mohrenweiser, H. Nonconservative amino acid substitution variants exist at polymorphic frequency in DNA repair genes in healthy humans. Cancer Research 58, 604-608 (1998).
97. Attia, J., Thakkinstian, A., D'Este, C. Meta-analyses of molecular association studies: methodologic lessons for genetic epidemiology. Journal of Clinical Epidemiology 56, 297-303 (2003).
98. Wei, S. Z. et al. Predictive value of ERCC1 and XPD polymorphism in patients with advanced non-small cell lung cancer receiving platinum-based chemotherapy: a systematic review and meta-analysis. Medical Oncology 28, 315-321 (2011).
99. Jiang, D. K. et al. Meta-analysis of association between TP53 Arg72Pro polymorphism and bladder cancer risk. Urology 76, 765 e761-767 (2010).
100. Thakkinstian, A. et al. Systematic review and meta-analysis of the association between {beta}2-adrenoceptor polymorphisms and asthma: a HuGE review. American Journal of Epidemiology 162, 201-211 (2005).
101. Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLOS Medicine 6, e1000097 (2009).
102. Parmar, M. K., Torri, V., Stewart, L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Statistics in Medicine 17, 2815-2834 (1998).
103. Tierney, J. F., Stewart, L. A., Ghersi, D., Burdett, S., Sydes, M. R. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 8, 16 (2007).
104. Cochran, W. G. The combination of estimates from different experiments. Biometrics 10, 101-129 (1954).
105. Higgins, J. P., Thompson, S. G. Quantifying heterogeneity in a meta-analysis. Statistics in Medicine 21, 1539-1558 (2002).
106. Higgins, J. P., Thompson, S. G., Deeks, J. J., Altman, D. G. Measuring inconsistency in meta-analyses. British Medical Journal 327, 557-560 (2003).
107. Lau, J., Ioannidis, J. P., Schmid, C. H. Quantitative synthesis in systematic reviews. Annals of Internal Medicine 127, 820-826 (1997).
108. DerSimonian, R., Laird, N. Meta-analysis in clinical trials. Controlled Clinical Trials 7, 177-188 (1986).
109. Mantel, N., Haenszel, W. Statistical aspects of the analysis of data from retrospective studies of disease. Journal of the National Cancer Institute 22, 719-748 (1959).
110. Begg, C. B., Mazumdar, M. Operating characteristics of a rank correlation test for publication bias. Biometrics 50, 1088-1101 (1994).
111. Egger, M., Davey Smith, G., Schneider, M., Minder, C. Bias in meta-analysis detected by a simple, graphical test. British Medical Journal 315, 629-634 (1997).